ZA959388B - Compositions comprising carbazoles and cyclodextrins - Google Patents

Compositions comprising carbazoles and cyclodextrins

Info

Publication number
ZA959388B
ZA959388B ZA959388A ZA959388A ZA959388B ZA 959388 B ZA959388 B ZA 959388B ZA 959388 A ZA959388 A ZA 959388A ZA 959388 A ZA959388 A ZA 959388A ZA 959388 B ZA959388 B ZA 959388B
Authority
ZA
South Africa
Prior art keywords
carbazoles
cyclodextrins
compositions
Prior art date
Application number
ZA959388A
Other languages
English (en)
Inventor
Jean-Louis Mesens
Herman M J Van Cauteren
Peter Putteman
Jozef Peeters
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA959388B publication Critical patent/ZA959388B/xx

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA959388A 1994-11-07 1995-11-06 Compositions comprising carbazoles and cyclodextrins ZA959388B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94203242 1994-11-07

Publications (1)

Publication Number Publication Date
ZA959388B true ZA959388B (en) 1997-05-06

Family

ID=8217355

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA959388A ZA959388B (en) 1994-11-07 1995-11-06 Compositions comprising carbazoles and cyclodextrins

Country Status (5)

Country Link
AU (1) AU3846395A (tr)
IL (1) IL115885A0 (tr)
TR (1) TR199501376A2 (tr)
WO (1) WO1996014090A1 (tr)
ZA (1) ZA959388B (tr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ330596A (en) 1998-06-05 2001-02-23 Dec Res Intravaginal devices allowing for increased uptake of active ingredients
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
CN100572363C (zh) 2000-11-17 2009-12-23 武田药品工业株式会社 咪唑衍生物、其制备方法及其用途
US6960586B2 (en) 2000-11-20 2005-11-01 Takeda Pharmaceutical Company Limited Imidazole derivatives, process for their preparation and their use
CA2431171A1 (en) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
GEP20156250B (en) 2009-06-26 2015-02-25 Novartis Ag 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
BR112012009262A2 (pt) * 2009-10-23 2019-09-24 Health Research Inc ''método para inibir a proliferação de células de câncer positivo para ar em um indivíduo diagnosticado com,ou qual se suspeita que tenha cânce positivo para ar e método para identificar se um indivíduo é um candidato para tratamento com uma composiçâo
JP5998137B2 (ja) 2010-08-04 2016-09-28 ペルフィキュア ファーマシューティカルズ,インコーポレイテッド 前立腺癌を処置するための併用療法
EP2627648A1 (en) 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
ES2656218T3 (es) 2011-04-28 2018-02-26 Novartis Ag Inhibidores de 17 alfa-hidroxilasa/C17,20-liasa
WO2014158875A1 (en) 2013-03-14 2014-10-02 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
US10093620B2 (en) 2014-09-12 2018-10-09 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
EP3528799A1 (en) 2016-10-24 2019-08-28 Pellficure Pharmaceuticals, Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310635D0 (en) * 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
AU3846395A (en) 1996-05-31
WO1996014090A1 (en) 1996-05-17
TR199501376A2 (tr) 1996-06-21
IL115885A0 (en) 1996-01-31

Similar Documents

Publication Publication Date Title
PL314956A1 (en) Siclicium-sodium-calcium glass compositions and their application
IL115891A0 (en) Hemorrhoidial compositions and their use
PL327659A1 (en) Disinfecting compositions and surface disinfecting methods
GB9616411D0 (en) Shampoo compositions and method
PL332699A1 (en) Immunomodulation methods and compositions
GB9525977D0 (en) Perfluoroelastomeric compositions and methods
IL126546A (en) Composition comprising aryl-piperazinyl-hetrocyclic salts and cyclodextrin
AU3641597A (en) Methods and compositions comprising r-ibuprofen
GB9525812D0 (en) Composition and use
AU2972597A (en) Compositions and uses thereof
ZA959388B (en) Compositions comprising carbazoles and cyclodextrins
PL331423A1 (en) Muporocin and chlorohexidrin containing compositions
ZA9510792B (en) Polymerization compounds and compositions
GB9624501D0 (en) Insecticial compositions and method
HUP9802997A3 (en) Antisudorific and/or deodorant compositions
US5478356B1 (en) Cyanoimides and compositions useful for bleaching
AU3674595A (en) Antianemic agent containing iron and difructose
PL331523A1 (en) Azolotrizines and azolopyrimidines
GB9415453D0 (en) Anti perspirant compositions
AUPO982097A0 (en) Methods and compositions for use therein
AU691690B2 (en) Acrolein-releasing composition and use thereof
HUP9900068A3 (en) Fuse-switch and/or fuse-disconnector
AU1468797A (en) Ghrh-rp compositions and methods
AU3227295A (en) Oil treatment and compositions therefor
AU2646795A (en) Detergent compositions comprising oleoyl sarcosinate and enzymes